XTX Topco Ltd Acquires New Stake in Masimo Co. (NASDAQ:MASI)

XTX Topco Ltd bought a new position in Masimo Co. (NASDAQ:MASI) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 17,157 shares of the medical equipment provider’s stock, valued at approximately $2,288,000.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MASI. FMR LLC raised its stake in shares of Masimo by 41.2% in the 3rd quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider’s stock worth $900,860,000 after buying an additional 1,970,883 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Masimo by 42.1% in the second quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock worth $153,314,000 after acquiring an additional 360,497 shares in the last quarter. Point72 Asset Management L.P. raised its position in Masimo by 107.8% in the second quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after acquiring an additional 351,523 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in Masimo by 23.2% in the 3rd quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock valued at $185,869,000 after acquiring an additional 262,370 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in shares of Masimo by 45.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider’s stock valued at $66,201,000 after purchasing an additional 165,257 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

MASI has been the topic of a number of research reports. Raymond James upgraded shares of Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a report on Wednesday, November 6th. Piper Sandler upped their price target on Masimo from $165.00 to $180.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Wells Fargo & Company lifted their target price on Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $167.00.

Masimo Price Performance

Shares of NASDAQ:MASI opened at $169.79 on Friday. The company’s fifty day moving average is $153.35 and its two-hundred day moving average is $131.52. The company has a market cap of $9.09 billion, a P/E ratio of 117.10 and a beta of 1.01. Masimo Co. has a 12-month low of $101.35 and a 12-month high of $178.27. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million for the quarter, compared to the consensus estimate of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Masimo’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share. Equities analysts expect that Masimo Co. will post 4.03 earnings per share for the current fiscal year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.